Last quarter (Q1 2024), Helix BioPharma's total revenue was C$―, a decrease of ― from the same quarter last year. In Q1, Helix BioPharma's net income was C$-1.25M. See Helix BioPharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jul 23	Jul 22	Jul 21	Jul 20	Jul 19
Total Revenue	-	-	-	-	C$ 0.00	C$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	C$ 6.07M	C$ 6.33M	C$ 6.05M	C$ 9.13M	C$ 8.62M	C$ 6.78M
Operating Income	C$ -6.07M	C$ -6.33M	C$ -6.05M	C$ -9.13M	C$ -8.62M	C$ -6.78M
Net Non Operating Interest Income Expense	C$ 37.00K	C$ 33.00K	C$ -14.00K	C$ 353.00K	C$ 0.00	C$ -10.00K
Other Income Expense	C$ -75.00K	C$ -5.00K	C$ 490.00K	C$ -90.00K	C$ 55.00K	C$ -22.00K
Pretax Income	C$ -5.94M	C$ -6.29M	C$ -6.56M	C$ -9.57M	C$ -8.56M	C$ -6.81M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	C$ -5.94M	C$ -6.29M	C$ -6.56M	C$ -8.04M	C$ -8.98M	C$ -7.53M
Basic EPS	C$ -10.03	C$ -0.03	C$ -40.00	C$ -0.06	C$ -0.07	C$ -0.07
Diluted EPS	C$ -0.04	C$ -0.03	C$ -0.04	C$ -0.06	C$ -0.07	C$ -0.07
Basic Average Shares	C$ 199.79B	C$ 193.23M	C$ 149.49M	C$ 137.89M	C$ 127.71M	C$ 106.65M
Diluted Average Shares	C$ 811.80M	C$ 193.23M	C$ 149.49M	C$ 137.89M	C$ 127.71M	C$ 106.65M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	C$ 6.07M	C$ 6.33M	C$ 6.05M	C$ -9.13M	C$ 8.62M	C$ 6.78M
Net Income From Continuing And Discontinued Operation	C$ -5.94M	C$ -6.29M	C$ -6.56M	C$ -8.04M	C$ -8.98M	C$ -7.53M
Normalized Income	C$ -4.69M	C$ -4.63M	C$ -4.82M	C$ -7.04M	C$ -8.41M	C$ -6.79M
Interest Expense	-	-	-	-	C$ 25.00K	C$ 13.00K
EBIT	C$ -5.93M	C$ -6.28M	C$ -6.55M	C$ -9.56M	C$ -8.54M	C$ -6.79M
EBITDA	C$ -5.91M	C$ -6.26M	C$ -6.53M	C$ -9.36M	C$ -8.32M	C$ -6.74M

Currency in CAD

Helix BioPharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing